Cognito Therapeutics today announced new study results showing that its Spectris AD therapy significantly slows Alzheimer’s progression.
The company designed its non-invasive Spectris device to deliver proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases. It restores brain electrical activity disrupted in Alzheimer’s disease (AD).
Spectris AD for at-home daily use has breakthrough device designation from the FDA as well.
Join us at DeviceTalks West — Oct. 15–16, 2025 in Santa Clara, California — for our panel exploring the future of neurotech featuring Christian Howell, CEO of Cognito Therapeutics. Register at West.DeviceTalks.com.
A post hoc analysis of the OVERTURE feasibility trial showed that Spectris AD treatment was associated with meaningful “time saved” across key measures of cognition, daily function, and brain structure on MRI, compared to sham treatment. Time saved reflects how much longer treated patients maintain cirtical functions before reaching the decline seen in untreated individuals.
OVERTURE enrolled 76 participants with mild-to-moderate Alzheimer’s disease. It included a six-month randomized, controlled phase followed by a 12-month open-label extension. In the initial six-month controlled phase, daily one-hour Spectris AD treatment led to 4.83 months of preserved ability to perform daily activities. Cognito said it also led to 4.56 months of delayed cognitive decline and 4.09 months of delayed whole-brain atrophy.
Benefits became more pronounced over the full 12-month study period, according to a news release. Cognito says it underscores the potential of Spectris AD to meaningfully delay Alzheimer’s progression and preserve quality of life.
“Our brains are electrical systems, and Alzheimer’s disrupts the rhythms that govern memory, cognition, and our ability to function,” said Christian Howell, CEO, Cognito Therapeutics. “Spectris AD represents a new class of therapy, one based in physics, that restores these natural neural oscillations without relying on a chemistry-based pharmacologic therapy. These findings show the potential to meaningfully slow disease progression by leveraging the potential of neuromodulation.”
Join us at DeviceTalks West — Oct. 15–16, 2025 in Santa Clara, California — for our panel exploring the future of neurotech featuring Christian Howell, CEO of Cognito Therapeutics. Register at West.DeviceTalks.com.
